10-Q: Palisade Bio Secures $138M, Advances IBD Drug PALI-2108

Palisade Bio reported positive Phase 1 clinical trial results for PALI-2108 in IBD, secured $138 million in a public offering, and addressed its going concern status, despite ongoing net losses and internal control weaknesses.

Summary

• Palisade Bio, a clinical-stage biopharmaceutical company, is focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, with PALI-2108 as its lead product candidate for ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD).
• The company announced positive results from the Phase 1 clinical study of PALI-2108 in healthy volunteers (SAD, MAD, FE cohorts) on May 27, 2025, and in UC patients on August 7, 2025, and September 17, 2025, meeting primary endpoints for safety, tolerability, and pharmacokinetics (PK).
• Promising signals of clinical improvement were observed in all five UC patients in the study's UC cohort.
• On October 16, 2025, the company dosed its first patients in an exploratory Phase 1b cohort for FSCD, which will evaluate safety, tolerability, PK, pharmacodynamics (PD), tissue-level pharmacology, and molecular responses.
• An underwritten public offering closed on October 2, 2025, raising gross proceeds of $138.0 million through the issuance of common stock and pre-funded warrants.
• Management believes the $138 million capital raise provides sufficient funding to support operations through major clinical development milestones, including Phase 2 primary efficacy readouts for PALI-2108 in UC (H2 2027) and FSCD (H1 2028).
• The company's net loss for the three months ended September 30, 2025, was $(2.868) million, an improvement from $(3.487) million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was $(7.882) million, an improvement from $(11.094) million in the prior year period.
• Research and development expenses decreased by $0.7 million (35%) for Q3 2025 compared to Q3 2024, primarily due to a shift from preclinical joint development costs to clinical trial expenses.
• General and administrative expenses increased by less than $0.1 million (5%) for Q3 2025 compared to Q3 2024, mainly due to increased shareholder services and legal expenses.
• A material weakness in internal controls over financial reporting persists as of September 30, 2025, related to financial closing and reporting processes, segregation of duties, and documentation.
• Stockholders approved a proposal on October 17, 2025, to authorize the Board of Directors to effect another reverse stock split at a ratio between 1-for-5 and 1-for-50 by December 31, 2025, though it has not yet been effected.
• Amended and Restated Executive Employment Agreements for J.D. Finley (CEO & CFO) and Mitchell Jones (CMO) became effective on September 4, 2025, updating their compensation and severance terms.

Sentiment

Score: 7

Explanation: The significant capital raise and positive early clinical data for the lead asset are strong positives, addressing immediate liquidity concerns and validating the development path. However, ongoing losses, the material weakness in internal controls, and the NSI-189 setback temper the overall sentiment, indicating continued high risk inherent in biopharmaceutical development.

Positives

• PALI-2108 Phase 1 clinical study met primary endpoints for safety, tolerability, and pharmacokinetics in healthy volunteers and UC patients.
• The UC cohort of the Phase 1 study showed promising signals of rapid and consistent clinical improvement in all five patients.
• A significant capital raise of $138.0 million gross proceeds from an underwritten public offering on October 2, 2025, substantially increased available working capital.
• Management has concluded there is no longer substantial doubt about the company's ability to continue as a going concern for one year following the financial statement issuance date.
• Net loss decreased to $(2.868) million for Q3 2025 from $(3.487) million for Q3 2024, and to $(7.882) million for 9M 2025 from $(11.094) million for 9M 2024.
• Research and development expenses decreased by 35% in Q3 2025 and 42% in 9M 2025 compared to prior year periods, reflecting a shift from preclinical to clinical stage activities and reduced joint development costs.

Negatives

• The company continues to incur net operating losses and negative cash flows from operations, with a net loss of $(2.868) million for Q3 2025 and $(7.882) million for 9M 2025.
• A material weakness in internal controls over financial reporting persists as of September 30, 2025, posing a risk of material misstatements.
• The Phase 2b study of ALTO-100 (formerly NSI-189) in major depressive disorder did not meet its primary endpoint, impacting a potential future milestone payment.
• The July 2025 Replacement Warrants are not yet exercisable due to delays in obtaining stockholder approval, which was initially adjourned multiple times and then cancelled, with a new meeting scheduled for December 3, 2025.
• The company will require additional funding to conduct future clinical activities beyond the current capital runway, which extends through Phase 2 readouts in H1 2028.
• The recent capital raises have resulted in significant dilution to existing stockholders.

Risks

• Business depends on successful clinical development, regulatory approval, and commercialization of therapeutic compounds, including PALI-2108, which is subject to substantial risks in drug development.
• Reliance on the license agreement with Giiant Pharma Inc. for PALI-2108 patents and applications; termination or non-compliance could materially harm the business.
• Data from Canadian clinical trials may not be accepted by the U.S. FDA or other foreign regulatory authorities, potentially requiring additional trials.
• Difficulty enrolling patients in clinical trials could delay or prevent progression of product candidates.
• Operations and PALI-2108 development will require substantially more capital than currently available, with no guarantee of securing additional funding on favorable terms.
• PALI-2108 may cause undesirable side effects or have unexpected properties, delaying approval, limiting commercial profile, or resulting in post-approval regulatory action.
• No assurance that product candidates will obtain regulatory approval; the process is expensive, time-consuming, and uncertain.
• Clinical studies of PALI-2108 may not yield successful results, leading to discontinuation of development.
• Completion of clinical trials may take longer than estimated or may not be completed at all.
• Even if PALI-2108 is approved, future regulatory reviews or inspections could result in suspension, withdrawal, facility closure, or substantial fines.
• Successful commercialization depends on adequate reimbursement levels and pricing policies from government authorities and health insurers.
• Potential product liability exposure could result in substantial costs and liabilities, limiting commercialization.
• Even if approved, PALI-2108 may fail to achieve broad physician and patient adoption for commercial success.
• Limited operating history and no revenues from product sales make it difficult to evaluate business success and future viability.
• Business model assumes revenue from marketing or out-licensing, but PALI-2108 is in early clinical development with a short development history.
• May choose to discontinue development or commercialization of product candidates at any time, adversely affecting operations.
• Inability to successfully in-license, acquire, develop, and market additional product candidates could impair business growth.
• Changes in funding for the FDA and other government agencies could hinder their ability to perform normal business functions, negatively impacting the business.
• Anticipated reliance on third-party Contract Research Organizations (CROs) and other third parties to conduct clinical trials; failure to meet requirements could prevent regulatory approval or commercialization.
• Dependence on two qualified suppliers for the active pharmaceutical ingredient (API) for PALI-2108; insufficient availability or inability to supply on commercially reasonable terms could adversely impact the business.
• Expectation to rely on collaborations with third parties for successful development and commercialization, which carries significant risks.
• Reliance on third-party contractors to supply, manufacture, and distribute clinical drug supplies; failure to maintain relationships could adversely affect the business.
• History of net operating losses and expectation to continue incurring them, with no guarantee of achieving profitability.
• Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements.
• May not be able to obtain, maintain, or enforce global patent rights or other intellectual property rights of sufficient breadth to prevent third-party competition.
• Failure to comply with obligations under intellectual property license agreements could lead to loss of license rights.
• Subject to patent infringement claims, which could result in substantial costs and liabilities and prevent commercialization.
• Subject to claims that officers, directors, employees, consultants, or independent contractors have wrongfully used or disclosed trade secrets of former employers or customers.
• Need to raise additional financing in the future, which may not be available on favorable terms or at all, leading to substantial dilution for existing stockholders.
• Common stock price may be highly volatile due to various factors, including clinical trial results, regulatory approvals, and market conditions.
• Common stock could be delisted from the Nasdaq Stock Market if compliance with listing standards is not maintained.
• Taking advantage of reduced disclosure and governance requirements as a smaller reporting company could make common stock less attractive to investors.
• No anticipation of paying dividends in the foreseeable future, making capital appreciation the sole source of gain for stockholders.
• Future sales of substantial amounts of common stock could adversely affect the market price.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Board has broad discretion to issue additional securities, potentially diluting existing stockholders.
• Business could be adversely affected by health pandemics or epidemics, global economic conditions, and geopolitical conflicts.
• Inadequate funding for government agencies (FDA, SEC) could hinder their operations and impact the business.

Future Outlook

The company anticipates submitting an Investigational New Drug Application (IND) to the U.S. FDA in the first half of 2026, leveraging data from the exploratory Phase 1b FSCD cohort and the Phase 1a/1b UC program. Following this, Phase 2 clinical programs are planned to assess PALI-2108's efficacy, safety, and tolerability in patients with FSCD and moderate to severe UC. Major clinical development milestones, including Phase 2 primary efficacy readouts for PALI-2108 in UC and FSCD, are expected in the second half of 2027 and first half of 2028, respectively. The recent $138 million capital raise is expected to fund operations through these milestones. The Board is authorized to effect another reverse stock split by December 31, 2025, but has not yet done so.

Management Comments

• Management has concluded that because of the gross proceeds raised from the recent equity offering in the amount of $138 million there is no longer a substantial doubt about the Company's ability to continue as a going concern for a period of one year following the date that these condensed consolidated financial statements are issued.
• We intend to use the net proceeds from the October 2025 Offering for working capital and general corporate purposes, including the development of PALI-2108 for the treatment of UC and FSCD.
• We believe the October 2025 Offering will provide sufficient capital to fund our operations through major clinical development milestones including a Phase 2 primary efficacy readout of PALI-2108 for UC in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 for FSCD in the first half of 2028.

Industry Context

Palisade Bio operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting autoimmune, inflammatory, and fibrotic diseases, with a focus on Inflammatory Bowel Disease (IBD). The company's precision medicine approach, utilizing biomarker-based patient selection for PDE4 inhibitors, aligns with a broader industry trend towards personalized medicine to improve treatment response rates. The failure of Alto Neuroscience's ALTO-100 (NSI-189) in MDD highlights the inherent risks and high failure rates in drug development, even for promising candidates. The significant capital raise is crucial for a clinical-stage company to advance its lead candidate, PALI-2108, through costly later-stage trials, a common challenge for smaller biotechs competing with larger pharmaceutical players.

Comparison to Industry Standards

• The positive Phase 1 results for PALI-2108 in safety, tolerability, and PK, along with promising clinical activity signals in UC patients, are a critical early step, aligning with the typical progression of drug candidates through initial human trials. However, Phase 1 trials are not powered for efficacy, and many drugs that succeed in Phase 1 do not advance through later stages.
• The failure of Alto Neuroscience's ALTO-100 (NSI-189) in its Phase 2b MDD study, despite being a previously licensed asset, underscores the high attrition rate in clinical development. This outcome is not uncommon in the industry, where only a small percentage of drug candidates ultimately reach market approval.
• The company's reliance on third-party CROs and CMOs for clinical trials and manufacturing is a standard industry practice for smaller biopharmaceutical companies that lack in-house infrastructure.
• The need for substantial additional capital to fund operations through major clinical development milestones (Phase 2 readouts in H2 2027 and H1 2028) is typical for clinical-stage biotechs, as R&D costs escalate significantly in later phases. The $138 million raise provides a runway, but further financing will be required, consistent with industry norms for companies without approved products generating revenue.

Management Changes

Corporate Governance

Legal Proceedings

• No claims or actions pending against the company through September 30, 2025, that are expected to have a material adverse effect on its business, liquidity, financial position, or results of operations.

Related Party Transactions

• The company has an obligation to make contingent consideration payments to Giiant Pharma, Inc. upon the achievement of development milestones for PALI-2108, with the first payment of $235,000 triggered on October 16, 2025.
• The company is obligated to pay a percentage of non-royalty licensing revenue received from Newsoara to the Regents of the University of California under the 2015 UC License.

Stakeholder Impact

• Shareholders: Significant dilution from recent equity offerings and warrant inducements, but also improved liquidity and extended operational runway. Potential for future reverse stock splits could impact share count and price. Positive clinical data could increase investor confidence.
• Employees: Amended employment agreements for key executives provide updated compensation and severance terms. The 2023 RIF is complete, but ongoing operational efficiency efforts may impact workforce.
• Customers (future): PALI-2108's progress offers potential new treatment options for patients with UC and FSCD.
• Creditors: Improved liquidity from the capital raise reduces immediate credit risk.
• Partners (Giiant Pharma): Achievement of the first development milestone for PALI-2108 triggers a payment to Giiant, demonstrating progress in the collaboration.

Next Steps

• Complete longer-term chronic safety and toxicology studies for PALI-2108.
• Continue evaluation of safety, tolerability, PK, PD, tissue-level pharmacology, and molecular responses in the exploratory Phase 1b cohort for FSCD.
• Submit an Investigational New Drug Application (IND) to the U.S. FDA in the first half of 2026 for PALI-2108.
• Initiate Phase 2 clinical programs to assess PALI-2108's efficacy, safety, and tolerability in patients with FSCD and moderate to severe UC.
• Obtain Warrant Stockholder Approval for the July 2025 Replacement Warrants at the next special meeting expected on December 3, 2025.
• The Board of Directors may effect another reverse stock split at a ratio between 1-for-5 and 1-for-50 on or before December 31, 2025.
• Alto Neuroscience expects topline data from its Phase 2b study of ALTO-100 in bipolar depression in the second half of 2026.
• Address and remediate the identified material weakness in internal controls over financial reporting.

Key Dates

Recommendation

Palisade Bio has made significant progress with its lead asset, PALI-2108, demonstrating positive Phase 1 clinical results and securing substantial funding to extend its operational runway through key Phase 2 milestones. This addresses immediate liquidity concerns and provides a clearer path for drug development. However, the company remains in a clinical stage with no revenue from product sales, continues to incur net losses, and faces inherent high risks associated with drug development, including the possibility of future clinical trial failures and the need for additional capital. The ongoing material weakness in internal controls and the delayed stockholder approval for warrants also present operational and governance risks. While the recent capital raise and clinical progress are positive, the long and uncertain path to commercialization, coupled with the high-risk profile of a biopharmaceutical company, suggests a 'hold' recommendation for seasoned investors. The stock may see volatility based on future clinical readouts and financing activities.

Keywords

Palisade Bio, PALI-2108, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Fibrostenotic Crohn's Disease, Biopharmaceutical, Clinical Stage, Phase 1 Clinical Trial, Drug Development, SEC Filing, 10-Q, Equity Offering, Warrant Inducement, Biomarker, PDE4 Inhibitor, Autoimmune Disease, Inflammatory Disease, Fibrotic Disease, Nasdaq